Browsing Category
CBD
Preparation and Evaluation of Directly Compressible Orally Disintegrating Tablets of Cannabidiol…
This study demonstrated the implementation of a liquisolid technique to formulate directly compressible orally disintegrating tablets (ODTs). Cannabidiol (CBD), a hydrophobic cannabinoid, was prepared as a liquisolid powder using microcrystalline cellulose–colloidal silicon dioxide as a…
Read More...
Read More...
Design of Liposomal Lidocaine/Cannabidiol Fixed Combinations for Local Neuropathic Pain Treatment
The administration of drug fixed combinations by nanocarriers is a new attractive approach since it can allow improvements in both the skin penetration of cargo compounds and their synergistic effects. The cutaneous administration of lidocaine (LD) and cannabidiol (CBD) combination can be useful for…
Read More...
Read More...
In Vitro Release, Mucosal Permeation and Deposition of Cannabidiol from Liquisolid Systems: The…
This work investigated the influence of liquid vehicles on the release, mucosal permeation and deposition of cannabidiol (CBD) from liquisolid systems. Various vehicles, including EtOH, nonvolatile low- and semi-polar solvents, and liquid surfactants, were investigated. The CBD solution was…
Read More...
Read More...
Effect of Lipid Vehicles on Solubility, Stability, and Topical Permeation of…
Delta-9-tetrahydrocannabinol (THC) is one of the most effective antinociceptive agents used in the treatment of peripheral neuropathy. THC is highly lipophilic and susceptible to thermal and oxidative degradation. Identifying appropriate solvents in which THC is stable as well as adequately…
Read More...
Read More...
Strategies for enhancing the oral bioavailability of cannabinoids
Introduction
Oral administration of cannabinoids is a convenient route of administration in many cases. To enhance the poor and variable bioavailability of cannabinoids, selected strategies utilizing proper delivery systems have been designed. Low solubility in the GI aqueous media is the first…
Read More...
Read More...
Pharmatrans SANAQ® introduces easily soluble CBD powder
Pharmatrans SANAQ® has added to its range of ingredients and excipients an easily soluble and high
purity powder containing between two and six per cent cannabidiol (CBD) as a flavorless
intermediate for food, feed, or cosmetics.
The end result is an easy-to-mix powder suitable for immediate…
Read More...
Read More...
Development of mucoadhesive carrier systems for flavoring agents and cannabidiol
The buccal mucosa represents an attractive site to realize both local and systemic effects. It is easily accessible and transbuccal drug delivery offers the opportunity to increase bioavailability of drugs by avoiding first-pass metabolism and intestinal drug degradation. But despite numerous…
Read More...
Read More...
The Transdermal Delivery of Therapeutic Cannabinoids
Recently, several studies have indicated an increased interest in the scientific community regarding the application of Cannabis sativa plants, and their extracts, for medicinal purposes. This plant of enormous medicinal potential has been legalised in an increasing number of countries globally. Due…
Read More...
Read More...
Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate…
The spread of SARS-CoV-2 and ongoing COVID-19 pandemic underscores the need for new treatments. Here we report that cannabidiol (CBD) inhibits infection of SARS-CoV-2 in cells and mice. CBD and its metabolite 7-OH-CBD, but not THC or other congeneric cannabinoids tested, potently block SARS-CoV-2…
Read More...
Read More...
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection–mass spectrometry was used for the discovery of botanical ligands to the…
Read More...
Read More...